^
Association details:
| Biomarker: | LAG3 expression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Suppressive immune profile in combined positive score positive head and neck cancer patients treated with immunotherapy
Published date:
05/26/2022
Excerpt:
Thirteen (37%) patients received pembrolizumab alone while pembrolizumab in association with chemotherapy (carboplatin or cisplatin and 5-fluorouracil) were administered intravenously to 22 (63%) patients....We showed both a statistically significant association between LAG3 expression and EP disease (p = 0.005)....Our findings showed that in CPS positive R/M HNSCC patients the contemporary expression of Treg cells and LAG3 could better select the patients primary resistant to anti-PD-1.
DOI:
10.1200/JCO.2022.40.16_suppl.e18014
Source:
Title:
Suppressive immune profile in combined positive score positive head and neck cancer patients treated with immunotherapy.
Published date:
05/26/2022
Excerpt:
The aim of our study is to investigate if the expression of peculiar biomarkers can affect the therapeutic efficacy of anti-PD-1....We showed both a statistically significant association between LAG3 expression and EP disease (p = 0.005)....Our findings showed that in CPS positive R/M HNSCC patients the contemporary expression of Treg cells and LAG3 could better select the patients primary resistant to anti-PD-1.
Secondary therapy:
carboplatin + 5-fluorouracil; cisplatin + 5-fluorouracil
DOI:
10.1200/JCO.2022.40.16_suppl.e18014
